Metsera Announces Positive Phase 1 Data of Amylin Candidate
Metsera, Inc. announced positive Phase 1 clinical trial data for MET-233i, a new ultra-long-acting amylin analog designed for monthly...
Jon Napitupulu
Lisaftoclax Data in Venetoclax-Refractory Patients from ASCO 2025
Ascentage Pharma presented Phase Ib/II data at the 2025 ASCO Annual Meeting for lisaftoclax, a Bcl-2 inhibitor, combined with...
Ziftomenib Monotherapy Shows Positive Pivotal Data at ASCO 2025
Kura Oncology and Kyowa Kirin announced positive Phase 2 trial results for ziftomenib, an oral menin inhibitor, in patients...
Onvansertib and Paclitaxel Show Promising Results in Metastatic TNBC
Cardiff Oncology announced positive data from a Phase 1b clinical trial of onvansertib combined with paclitaxel for metastatic triple-negative...
4D Path Biomarker Predicts Breast Cancer Treatment Response
4D Path presented groundbreaking findings at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, demonstrating that their...
Amtagvi® Five-Year Analysis in Advanced Melanoma: Journal of Clinical Oncology
Iovance Biotherapeutics announced five-year follow-up results from the Phase 2 C-144-01 trial of its T cell therapy, Amtagvi (lifileucel),...
ISB 2001 Shows High Response Rates in Relapsed/Refractory Multiple Myeloma
Ichnos Glenmark Innovation (IGI) presented positive Phase 1 trial data for ISB 2001, a novel trispecific antibody targeting BCMA,...
Rosnilimab Shows Positive Phase 2b Results in RA Trial
AnaptysBio’s investigational drug, rosnilimab, has shown promising results in a Phase 2b trial for rheumatoid arthritisarthritis (RA). The drug...
Akeega® Improves Efficacy in HRR-Mutated mHSPC
Johnson & Johnson’s Phase 3 AMPLITUDE study demonstrates that the combination of niraparib and abiraterone acetate with prednisone significantly...
FlexiTouch® Plus Improves Lymphedema in Head & Neck Cancer Survivors
Tactile Medical presented two-month data from the largest randomized controlled trial on head and neck cancer-related lymphedema at the...